CStone Pharma announces inclusion of Cejemly as a first-line combination therapy for NSCLC in ESMO guideline: Suzhou, China Tuesday, February 11, 2025, 13:00 Hrs [IST] CStone Phar ...

Regeneron UK Limited today announced that the Scottish Medicines Consortium (SMC) has accepted Libtayo® (cemiplimab) for use on the National Health Service as a second-line monotherapy treatment for ...

Sangamo (SGMO) announced updated data from the Phase 1/2 STAAR study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene ...

Sangamo (SGMO) reported positive updated data from a Phase 1/2 study of its gene therapy candidate ST-920 in the treatment of Fabry disease. Read more here.

Cancer still eludes treatment, and tumors frequently evolve resistance mechanisms to get around medications. By making cancer ...

Results from the Phase III NRG Oncology RTOG 0920 (NRG-RTOG 0920) trial assessing postoperative radiotherapy with or without concurrent cetuximab for selected patients with squamous cell cancer of the ...

Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Genetics is key to the development of cancer and also in the progression. Some inherited mutations confer a susceptibility to ...

Again, even though the EGFR niche might give Datroway a way into ... developed a new biomarker that measures TROP2 expression both on tumor cell surface and in the cytoplasm.